The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.
The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.
The Calmer Co. International Limited has secured a FJD2.64 million loan from Fiji Development Bank to acquire its Navua manufacturing site, marking a strategic step to enhance production and market presence in the global kava industry.